E-viri
Recenzirano
-
Saboundji, Karima; Auliac, Jean-Bernard; Pérol, Maurice; François, Géraldine; Janicot, Henri; Marcq, Marie; Dubos-Arvis, Catherine; Renault, Aldo; Guisier, Florian; Odier, Luc; Gervais, Radj; Chouaïd, Christos
Targeted oncology, 08/2018, Letnik: 13, Številka: 4Journal Article
Background The prognosis of patients with non-small cell lung cancer (NSCLC) who develop leptomeningeal metastasis (LM) is poor. Objective To assess the clinical efficacy of osimertinib, a third-generation tyrosine-kinase inhibitor (TKI), in patients with epidermal growth-factor receptor ( EGFR )-mutated NSCLCs and LM. Patients and Methods Retrospective study of NSCLC patients with osimertinib-treated EGFR -mutated NSCLC and LM. Results Twenty patients (mean age, 61.2 years; 70% women) with adenocarcinoma NSCLC were included in the study. EGFR mutations were reported in exons 18 ( n = 2), 19 ( n = 7), and 21 ( n = 11). Before starting osimertinib, patients had received a mean of 2.3 treatment lines. When LM was diagnosed, all patients had clinical symptoms. Sixteen (80%) patients had a performance status ≥2. At osimertinib initiation, 13 (65%) patients harbored the EGFR -T790M–resistance mutation. Osimertinib was started at 80 ( n = 17), 160 ( n = 2), or 40 mg/day ( n = 1). All 13 (100%) patients with the T790M mutation and 4 (57%) of those without it obtained clinical responses. Among the 11 radiologically assessable patients, 9 (82%) responded, with 5 responses reported within 15 days after treatment initiation. Median overall survival and progression-free survival were 18.0 and 17.2 months, respectively, from the start of osimertinib. Conclusions In this non-selected population, osimertinib had remarkable efficacy in NSCLC patients with LM irrespective of the presence of the EGFR -T790M–resistance mutation. Osimertinib efficacy was rapid in several patients, even some with poor performance status.
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.